Article Details
Retrieved on: 2022-08-12 16:48:20
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
NEW YORK – Health Canada this week approved AstraZeneca and Merck's PARP inhibitor Lynparza (olaparib) as adjuvant treatment for high-risk, ...
Article found on: www.precisiononcologynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here